Newstin ORGANIZING THE NEWS

THIS WEEK'S PICKS

in all

New to Newstin? Take a look at what we are doing...

* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

Full Coverage

Tekmira Pharmaceuticals Selects Two Products for Clinical Development in 2009

tmcnet.com

Jul 21, 2008

Story Timeline: 83 days

VANCOUVER, BRITISH COLUMBIA, July 21 / MARKET WIRE/ -- Tekmira Pharmaceuticals Corporation ("Tekmira") (TSX: TKM) announced today that it has selected ApoB SNALP and PLK1 SNALP as its two lead product candidates and plans to advance both into clinical development in 2009. Mark J. Murray, Tekmira's President and CEO, said, "Following the close of the business combination between Tekmira and Protiva, we committed to taking a close look at the new company's combined product portfolio and future milestones. We are now moving forward with a clear two-part strategy: first, to focus on developing products exclusively in the RNA interference (RNAi) therapeutics field with our two lead product candidates, ApoB and PLK1, and second, to support our partners as they advance products based on our leading delivery technology." Tekmira's... [read full story]

Add Comment